Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recruiting

Phase 2

Nivolumab & IpilimumabTesting Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05904080

Conditions

Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Cabozantinib S-malate

Computed Tomography

Ipilimumab

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-30.